This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Ramey, W. G. Articles by Fitzpatrick, H. F. Search for Related Content PubMed PubMed Citation Articles by Ramey, W. G. Articles by Fitzpatrick, H. F.

Detection of Breast Tumor Antigen-sensitive Circulating T-Lymphocytes by Antigen-stimulated Active Rosette Formation^1,2

Department of Surgery, St. Luke's Hospital Center, and Columbia University, New York, New York 10025

Preoperative circulating human breast tumor-associated antigen (BTA)-sensitive T-lymphocytes were detected in breast carcinoma patients by the antigen-stimulated active rosette-forming T-cell (AgARFC) assay. Incubation of peripheral lymphocytes isolated from tumor-bearing patients with either of two soluble allogeneic BTA extracts (BTA₁ and BTA₂) produced higher percentages of AgARFC than did incubation in antigen-free media (ARFC). The circulating BTA-sensitive T-cell subpopulation, as %AgARFC — %ARFC, of 56 patients found to have invasive breast cancer was 6.4 ± 0.9% (S.E.) for BTA₁ and 7.4 ± 0.7% for BTA₂. These values were significantly higher than the mean responses to corresponding isologous lymphocyte histocompatibility antigen (HA) extracts (HA₁ and HA₂), 1.1 ± 0.5% for HA₁ and 2.2 ± 0.8% for HA₂ (p < 0.001). In contrast, mean AgARFC responses of lymphocytes from patients with benign mastopathy to BTA or to HA were not significantly increased. The means of paired BTA-HA differences in %AgARFC response for 56 breast carcinoma patients were significantly higher than values obtained for 87 patients with benign mastopathy (p < 0.001), for 16 patients with nonmammary carcinomas (p < 0.001), or for 18 clinically normal subjects (p < 0.001). Similarly, significant differences were found for the corresponding absolute numbers of circulating BTA-sensitive T-cells per cu mm of peripheral blood. Differences in peripheral lymphocyte counts, total T-cell levels, and ARFC levels were not highly significant in any of the groups of patients studied. The AgARFC assay provided a specific, rapid, and reproducible assay for detecting peripheral blood T-lymphocyte sensitized to BTA in breast cancer patients.

¹ Supported by a grant from The Clark Foundation, New York, N. Y.

² Preliminary report was presented at the 63rd Annual Meeting of the Federation of American Societies for Experimental Biology, April 7, 1979, Dallas, Texas (39).

³ To whom requests for reprints should be addressed, at Department of Surgery, St. Luke's Hospital Center, Amsterdam Avenue at 114th Street, New York, N. Y. 10025.

Received 4/23/79. Accepted 8/20/79.